Utama › Kanser Ginjal (Karsinoma Sel Renal)
Kajian klinikal Kanser Ginjal (Karsinoma Sel Renal) sedang mengambil peserta di AS
134 kajian untuk Kanser Ginjal (Karsinoma Sel Renal) sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX35 kajian
- New York City, NY27 kajian
- Nashville, TN23 kajian
- Dallas, TX23 kajian
- St. Louis, MO23 kajian
- Los Angeles, CA20 kajian
- Boston, MA16 kajian
- Baldwin Park, CA16 kajian
- Philadelphia, PA15 kajian
- Pittsburgh, PA15 kajian
- Queens, NY15 kajian
- Rochester, MN14 kajian
- Cleveland, OH14 kajian
- Jacksonville, FL14 kajian
- San Diego, CA14 kajian
- Washington, DC13 kajian
- New Haven, CT13 kajian
- Columbus, OH13 kajian
- Durham, NC12 kajian
- Omaha, NE12 kajian
- Edison, NJ12 kajian
- San Antonio, TX12 kajian
- Ann Arbor, MI12 kajian
- Phoenix, AZ11 kajian
- Portland, OR11 kajian
- San Francisco, CA11 kajian
- Detroit, MI10 kajian
- Baltimore, MD10 kajian
- Grand Rapids, MI10 kajian
- Atlanta, GA10 kajian
- Arlington, VA9 kajian
- Seattle, WA9 kajian
- Aurora, CO9 kajian
- Santa Monica, CA8 kajian
- Charlotte, NC8 kajian
- Milwaukee, WI8 kajian
- Chicago, IL8 kajian
- Miami, FL8 kajian
- Oklahoma City, OK8 kajian
- Denver, CO8 kajian
Mengikut negeri
- Alabama7 kajian
- Arizona22 kajian
- Arkansas6 kajian
- California51 kajian
- Colorado15 kajian
- Connecticut13 kajian
- Florida31 kajian
- Georgia12 kajian
- Idaho4 kajian
- Illinois14 kajian
- Indiana8 kajian
- Iowa9 kajian
- Kansas5 kajian
- Kentucky9 kajian
- Louisiana7 kajian
- Maine3 kajian
- Maryland17 kajian
- Massachusetts18 kajian
- Michigan29 kajian
- Minnesota20 kajian
- Mississippi4 kajian
- Missouri23 kajian
- Montana3 kajian
- Nebraska12 kajian
- Nevada4 kajian
- New Hampshire4 kajian
- New Jersey16 kajian
- New Mexico5 kajian
- New York36 kajian
- North Carolina19 kajian
- North Dakota3 kajian
- Ohio26 kajian
- Oklahoma8 kajian
- Oregon11 kajian
- Pennsylvania26 kajian
- Rhode Island6 kajian
- South Carolina12 kajian
- South Dakota4 kajian
- Tennessee27 kajian
- Texas56 kajian
- Utah7 kajian
- Vermont3 kajian
- Virginia13 kajian
- Washington12 kajian
- West Virginia4 kajian
- Wilayah Columbia7 kajian
- Wisconsin12 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07300241Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06265285A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Mengambil pesertaFasa 2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05155033A Phase 1 Study of the Safety and Tolerability of CTX-10726
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07419841Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Mengambil pesertaFasa 1/2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07049926A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05176483Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05287945The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07285044Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT03866382Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT04981509REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07594106DESTINY-PANTUMOUR04
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 130 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04981119A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07489495Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
Umur 18 hingga 100 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07748988Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06047379A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07293351Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06863311A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT07688187Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05267626Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 18 Sep 2026 · NCT07828704Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.